Immunocore Holdings plc Transfers Of Cumulative Gain Loss With in Equity
Immunocore Holdings plc (IMCR) reported Transfers Of Cumulative Gain Loss With in Equity of GBP 3.84 million for the 12-month period ending 2020-12-31, per its 20-F filed 2023-03-01.
Discontinued › Income Statement › Other Income
ifrs-full:TransfersOfCumulativeGainLossWithinEquity · last filed 2023-03-01
| Period end | Transfers Of Cumulative Gain Loss With in Equity 12 month |
|---|---|
| 2020-12-31 | 3.84M GBP 20-F · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |